

ORIGINAL PAPER

Chronic Kidney Disease with Special Reference to Dyslipidemia

Sharma Manjuri¹, Baruah Swaroop Kr², Teron Mithu³, Das Himanab Jyoti⁴

Received on November 19, 2015; editorial approval on January 1, 2016

ABSTRACT

Background: Lipid abnormalities in chronic kidney disease (CKD) are significant, because atherosclerotic heart disease is the foremost cause of morbidity and mortality in patients with end stage renal disease. The growing recognition that dyslipidemia is a major risk factor for coronary heart disease has prompted interest in the identification and management of abnormalities in plasma lipids and lipoproteins. *Method:* It was hospital based observational study conducted from January 2014 to January 2015 in Department of Medicine and Nephrology, Gauhati Medical College, where 50 patients of chronic kidney disease were included and evaluated for dyslipidemia. *Results:* Most common presenting symptoms were swelling of legs (80%), followed by anorexia, nausea, vomiting (72%), puffiness of face (64%), decrease urine output (60%). 100% patients presented with anemia, 80 % with edema and 76% with hypertension. 24 (48%) patients had normal ECG, 13 (26%) patients had left ventricular hypertrophy (LVH). 13 patients (26%) had hyperkalemia. Mean total cholesterol (TC) was 189±43.3mg/dl, triglyceride 174±60.7, high density lipoprotein (HDL) 36.51 ±5.1, very low density lipoprotein (VLDL) 34.88±12.15, low density lipoprotein (LDL) 116.49±38.34 and HDL/ TC ratio 0.2002±0.0478. *Conclusion:* Dyslipidemias are the important predictive indices for the risk of developing coronary artery disease in chronic kidney disease patients, and so early evaluation and treatment of dyslipidemia may improve the cardiovascular outcome.

Keywords: Chronic kidney disease, dyslipidemia

INTRODUCTION

Lipid abnormalities in chronic kidney disease (CKD) are significant, because atherosclerotic heart disease is the foremost cause of morbidity and mortality in patients with end stage renal disease. Cardiovascular disease is a major cause of morbidity and mortality among patients with chronic kidney disease.¹⁻³ The growing recognition that dyslipidemia is a major risk factor for coronary heart disease has prompted interest in the identification and management of abnormalities in plasma lipids and lipoproteins. In CKD the most prevalent lipid disorders are hypertriglyceridemia and decrease in high density lipoprotein (HDL) concentration. Low density lipoprotein (LDL) levels are usually normal or marginally increased.⁴⁻⁶ Also there are reports available regarding accelerated atherosclerosis in chronic kidney disease due to altered lipid metabolism. In recent years, the levels of high density lipoproteins have gained importance in view of the fact that increasing reports are available incriminating decreased high density lipoprotein (HDL) levels as one of risk factors for cardiovascular disease. So, the analysis

Address for correspondence and reprint:

¹Associate Professor, Dept Of Nephrology, Gauhati Medical College and Hospital, Guwahati, Assam
(corresponding author)

Mobile: 09435553482

Email: manjurisharma@yahoo.com

²Professor of Medicine, Gauhati Medical College and Hospital

³PGT of Medicine, Gauhati Medical College and Hospital

⁴Senior Resident, Dept Of Nephrology, Gauhati Medical College and Hospital

of lipoprotein subclass in chronic kidney disease patients is very much essential to assess the clinical outcome.

Aims: (i) To identify the different lipoprotein fractions in patients with chronic kidney disease and **(ii)** To identify the pattern of dyslipidemias in conservatively treated patients and in patients managed with hemodialysis.

MATERIALS AND METHODS

The present study was a hospital based observational study conducted from January 2014 to January 2015 in Department of Medicine and Department of Nephrology (both OPD and Indoor), Gauhati Medical College and Hospital, where 50 patients of chronic kidney disease were included. Chronic kidney disease (CKD) is defined as kidney damage or glomerular filtration rate (GFR) below 60 ml/min per 1.73 m² for 3 months or more irrespective of the cause. CKD patients are divided into 5 stages according to GFR as shown in **Table 1**.

Table 1 Stages of Chronic kidney disease

Stages	GFR (ml/min)
1	≥ 90
2	60- 89
3	30- 59
4	15- 29
5	< 15

Chronic kidney disease was diagnosed by clinical, biochemical and ultrasonographic evidence. Patients of chronic kidney disease age more than 12 years were included. Patients with diabetes mellitus, thyroid and liver disease, history of alcohol consumption and smoking, lipid lowering drugs and patient on CAPD (continuous ambulatory peritoneal dialysis) were excluded. The patients included in the study were subjected to a detailed history, physical examination and laboratory tests. Study of lipid profile was done by enzymatic method by using autoanalyser.

RESULTS

In the present study, 50 patients of CKD were included, out of which 31 patients (62%) were male and 19 patients (38%) were female. On decade wise grouping, maximum numbers of patients were in the age group 41-50 years (30%). Mean age for male was 46.6 years and that for female was 45.4 years. Male to female ratio in the study group was 1.6:1. The age and sex distribution of the patients were shown in **Table 2**.

Table 2 Showing the age and sex distribution of the patients

Age Group	Total No Of Cases	Percentage	Male	Percentage	Female	Percentage
<20	2	4	1	50	1	50
21-30	8	16	4	50	4	50
31-40	5	10	5	100	0	0
41-50	15	30	9	60	6	40
51-60	10	20	5	50	5	50
61-70	9	18	6	66.66	3	33.34
>70	1	2	1	100	0	0
Total	50	100	31		19	

Most common presenting symptom was swelling of legs (80%). Anorexia, nausea, vomiting was present in 72% of patient, puffiness of face was present in 64 % of patients, decreased urine output was present in 60 % of patients, and breathing difficulty was present in 32% of patients. All the patients (100%) included in the study had anemia, 80 % of patient had edema, 76% of patient had hypertension, 36% of patient had ascites, 32% of patient had pleural effusion, 32% of patients had acidotic breathing, 20% of patient had raised JVP and 16% of patient had altered sensorium. The presenting symptoms and the clinical signs are shown in **Table 3** and **Table 4** respectively.

Table 3 Showing the presenting symptoms among CKD patients

	Swelling of legs	Puffiness of face	Decrease urine output	Anorexia nausea vomiting	Breathing difficulty
Patients	40	32	30	36	16
Percentage	80%	64%	60%	72%	32%

Table 4 Showing the clinical signs in CKD patients

	Anemia	Hypertension	Edema	Raised JVP	Ascites	Pleural effusion	Acidotic breathing	Altered sensorium
Patients	50	36	40	10	18	16	16	8
Percentage	100%	72%	80%	20%	36%	32%	32%	16%


Nine (9) patients were in stage 3, 18 patients were in stage 4 and 23 patients were in stage 5. Stage 3 and stage 4 patients were treated conservatively and stage 5 patients were on renal replacement therapy (hemodialysis). Mean values for urea was 135.26±41.99 mg/dl and creatinine 11.12±5.09 mg/dl.

Out of 50 patients, 24 (48%) patients had normal electrocardiogram (ECG). 13 (26%) patients had left ventricular hypertrophy (LVH) of which 9 (69.23%) were male and 4 (30.77%) were female. 13 patients (26%) had changes of hyperkalemia of which 8 (61.54%) were male and 5 (38.46%) were female.

The mean total cholesterol (TC) was 189±43.3mg/dl, mean triglyceride was 174±60.7 mg/dl, mean HDL was 36.51 ±5.1 mg/dl, mean very low density lipoprotein (VLDL) was 34.88±12.15 mg/dl, mean low density lipoprotein (LDL) was 116.49±38.34 mg/dl and HDL/ TC ratio 0.2002±0.0478. The mean values of the lipid profiles are shown in the **Table 5** and **Graph 1** below:

Table 5 Showing the biochemical (lipid profile) data in CKD patients (Mean ± SD) mg/dl

Total cholesterol	189±43.3
Triglyceride	174±60.7
HDLc	36.51±5.1
LDLc	116.49±38.34
VLDLc	34.88±12.15
HDL/TC	0.2002±0.0478




Graph 1 Lipid profile in CKD patients

The lipid profile of the patients in the conservative group and in the hemodialysis group are shown in **Table 6** and **Graph 2** below

Table 6 Showing lipid profile in the conservative and hemodialysis group

Group	Conservative Treatment (N=27)	Dialysis (n=23)	t-value	p-value
Total Cholesterol	191.990 ±50.73	179.826 ±31.66	0.7595	ns
Triglyceride	155.176±47	199.01±70	2.052	Sig p<0.05
HDLc	36.1±5.76	35.7±5.20	0.1964	ns
LDLc	125.38±44.3	104.87 ±25.10	1.492	ns
VLDLc	31.27±9.525	39.82±14	1.991	ns
HDL/TC	0.20±0.053	0.202 ±0.0405	0.1130	ns



Graph 2 Comparison of lipid profile between conservative and dialysis group

The above table 6 and graph 2 shows comparison of biochemical mean values of TC, TG, HDL, and HDL/TC between patients managed conservatively and patients managed with hemodialysis. Mean total cholesterol in patients on conservative treatment was 191.99 ± 50.73 mg/dl and for patients on hemodialysis it was 179.826±31.66 mg/dl and this difference was statistically not significant (P>0.05). The mean triglycerides in patients of CKD on conservative treatment was 155.1764±7 mg/dl and the mean triglycerides in hemodialysis group was 199.01±70mg/dl. This difference was statistically significant (P<0.05). The mean HDL value in conservative treatment group was 36.1±5.76 mg/dl and the mean HDL value in hemodialysis group was 35.7±5.20mg/dl and this difference was statistically not significant. The mean LDL value in CKD patients on conservative group was 125.38±44.3mg/dl and the mean LDL value in hemodialysis

group was 104.87 ± 25.10 mg/dl and this difference was statistically not significant. The mean VLDL values for patients in conservative group and hemodialysis group was 31.27 ± 9.525 mg/dl and 39.82 ± 14 mg/dl respectively and this difference was statistically not significant. The difference in mean values of HDL/TC in both conservative treatment group and hemodialysis group was also statistically not significant.

On comparing mean values of TC, TG, HDL, LDL, VLDL values between male and female patients, there was increase in TG and decrease in HDL in male patients and there was increase in TC and LDL in female patients. However these differences were statistically not significant ($P > 0.05$)

33 patients (66%) had total cholesterol < 200 mg/dl (desirable range) and 17 patients (34%) had abnormal value, among them 12 (24%) patients had borderline high values (200- 239 mg/dl) and 5 (10%) patients had high values (> 240 mg/dl). 19 patients (38%) had normal TG values (< 150 mg/dl), 31 patients (62%) had elevated TG values, among them 16 patients (32%) had TG in borderline high (150-199 mg/dl) range and 15 patients (30%) had TG in high (200-499 mg/dl) range. This was statistically significant ($P < 0.05$). 41 patients (82%) had HDL values < 40 mg/dl, 9 patients (18%) had HDL > 40 mg/dl. 17 patients (34%) had normal LDL levels (< 100 mg/dl), 17 patients (34%) had near optimal LDL levels (101-129 mg/dl), 8 (16 %) had borderline high LDL levels (130-159 mg/dl), 6 (12 %) had high LDL levels (160- 189 mg/dl) and 2 (4 %) patients had very high LDL levels (> 130 mg/dl). This was statistically not significant ($p > 0.05$).

DISCUSSION

In the present study, out of 50 patients of CKD, 31 patients (62%) were male and 19 patients (38%) were female. Maximum number of patients was in the age group 41-50 years (30%) and the mean age for male was 46.6 years and that for female was 45.4 years.

In the study group of CKD patients 18% were in stage 3, 36% stage 4, 46% stage 5. Total 27 patients were treated conservatively (stage 3 & stage 4) and 23 patients (stage 5) were treated by hemodialysis.

In this study, triglyceride levels were markedly elevated. P.O Attman et al.⁷ stated that hypertriglyceridemia is the most common plasma lipid abnormality found in patients of chronic kidney disease.

The cause for hypertriglyceridemia in chronic kidney

disease patients has not been clearly delineated. Available data derived from Kinetic studies have demonstrated that reduced catabolism of triglycerides is the predominant defect due to deficiency of lipoprotein lipase⁷⁻⁹ or hepatic triglyceride lipase or both. Reasons for decrease in activity of these enzymes are not clear. It can be possibly due to:

- Presence of circulatory inhibitor of lipolytic enzymes in the serum¹.
- Changes in apoprotein concentrations which can effect lipoprotein lipase activity
- Insulin resistance seen in renal insufficiency⁷
- Alteration of lipoprotein substrate¹⁰

The relationship between hypertriglyceridemia and atherosclerotic heart disease is far less clear. Thomas Quaschnig et al.¹¹ reported that combined hyperlipidemia (elevated cholesterol and triglycerides) with low HDL cholesterol reflects more atherogenic condition.

In the present study, there was decrease in high density lipoprotein (HDL) cholesterol seen in CKD patients. P.O. Attman et al.⁷ found decrease in plasma high density lipoprotein (HDL) cholesterol concentration in patients with chronic kidney disease. It was also reported that decreased HDL was associated with decrease in both the fractional catabolic rate and the total synthetic rate of ApoA1/HDL. The slow fractional catabolic rate of Apo A1 in patients with chronic kidney disease could be a primary event resulting from a decrease in synthesis or secretion of Apo A1. John D Bagdade et al.¹² demonstrated that patients of renal failure treated by chronic dialysis have lower HDL levels compared to controls.

There was marginal increase of serum total cholesterol in chronic kidney disease patients. P.O. Attman et al.⁷ in their study showed no significant change in levels of total cholesterol. Thomas Quaschnig et al.¹¹ reported combined hyperlipidemia (elevated total cholesterol and triglycerides) in their study.

The present study showed no significant increase in LDL levels in CKD patients. In uremia LDL lipoproteins are qualitatively altered. Marion Morena et al.¹³ reported that there was increase in small, dense LDL sub-fractions in hemodialysis patients.

Hypertriglyceridemia observed in hemodialysis patients results from a reduced lipolysis of TG rich VLDL that leads to the accumulation of partially metabolized remnant lipoproteins (IDL and TG rich LDL). This lipoprotein catabolism impairment is usually associated with reduced

levels of HDL affecting reverse cholesterol transport. Such defect in atherogenic lipoprotein catabolism may predispose to the formation of small dense LDL particles, which appear to be more sensitive to ex vivo oxidation.

On comparing the lipid profile values between dialysis and conservatively managed patient it was seen that total cholesterol levels were decreased in patients on hemodialysis (HD) as compared to patients treated by conservative line but this difference was statistically not significant ($P>0.05$). HDL levels were marginally low in patients of HD compared to conservatively treated patients but this was also statistically not significant. VLDL in HD group was modestly increased compared to conservative group but this was also statistically not significant ($P>0.05$). LDL values were modestly low in patient treated with hemodialysis as compared to patients treated conservatively however this difference was statistically not significant. There was significant increase in triglycerides in patients treated with hemodialysis compared to patients on conservative treatment ($P<0.05$).

John D. Bagdade et al.¹² studied lipid profile in 27 patients of CKD of which 13 patients were on conservative treatment and 14 patients were on dialysis and they found that triglycerides were found to be elevated in both non dialysed and dialysed CKD patients.

Morena Marion et al.¹³ in their study on hemodialysis patients stated that hemodialysis patients are exposed to several atherogenic factors resulting from qualitative and functional lipid abnormalities, including triglyceride rich particles, increased susceptibility to LDL oxidation and impairment of HDL protective effects.

S.M. Alamet al.¹⁴ studied serum lipoprotein fractions in patients of CKD of conservatively managed group and those on maintenance hemodialysis (HD). The total cholesterol in the conservative group was 232.3 ± 56 and in HD group was 160.8 ± 56.4 , triglycerides in the conservative group was 243.7 ± 119 and in HD group was 145.4 ± 24.3 , HDL in the conservative group was 19.0 ± 6.1 and in HD group was 12.17 ± 5.1 . LS Ibels et al.¹⁵ also studied serum lipoprotein fractions in patients of CKD of conservatively managed group and those on maintenance hemodialysis (HD). The total cholesterol in the conservative group was 236 ± 24 and in HD group was 216 ± 57 , triglycerides in the conservative group was 273 ± 57 and in HD group was 237 ± 112 , HDL in the conservative group was 22 ± 6 and in HD group was 24 ± 9 , LDL in the conservative group was 131 ± 42 and in HD group was

116 ± 34 and VLDL in the conservative group was 55 ± 40 and in HD group was 47 ± 28 . In the present study total cholesterol in the conservative group was 191.99 ± 50.73 and in HD group was 179.826 ± 31.66 , triglycerides in the conservative group was 155.176 ± 47 and in HD group was 199.01 ± 70 , HDL in the conservative group was 36.1 ± 5.76 and in HD group was 35.7 ± 5.20 , LDL in the conservative group was 125.38 ± 44.3 and in HD group was 104.87 ± 25.10 and VLDL in the conservative group was 31.27 ± 9.525 and in HD group was 39.82 ± 14 . The important finding in the present study was significant increase in triglycerides in the patients on hemodialysis.

CONCLUSION

One of the known metabolic changes associated with CKD is lipid disorders. Significant increase in TG, VLDL and reduction in HDL and HDL/total cholesterol ratio have been reported in various previous studies and the present study too has observed the same results. Dyslipidemias are the important predictive indices for the risk of developing coronary artery disease in chronic kidney disease patients, and so early evaluation and treatment of dyslipidemia may improve the cardiovascular outcome.

Conflict of interest: None declared.

Ethical clearance: Taken.

Source of funding: None declared.

Declarations: (1) The article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties; (2) The article has not been published (whole or in part) elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein; (3) All author (s) have contributed sufficiently in the article to take public responsibility for it and (4) All author (s) have reviewed the final version of the above manuscript and approve it for publication.

REFERENCE

1. King W. MA, Edward L. Greene, Leopold Rajj. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. *Am J kidney Dis* 1992;6:505-513.
2. Eggers PW. Mortality rates among dialysis patients in Medicare's end-stage renal disease program. *Am J. kidney Dis* 1990;15:414-421.
3. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. *Kidney Int* 1982;22:304-308.

4. Lidner A, Charra B, Sherrard D. Accelerated atherosclerosis in prolonged maintainance hemodialysis. N Engl J Med 1974;290:697-701.
5. Tetsuo Shoji, EijiIshimura, Masaaki Inaba, Tsutomu Tabata, Yoshiki Nishizawa. Atherogenic Lipoproteins in end stage renal disease. Am J kidney dis 2001;38:S30-S33.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J kidney dis 1998;32:S112-S119.
7. P.O Attman, Alaupovic P, M. Tavella, C Knight –Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol dial transplant 1996;11:63-69.
8. P.O Attman, Samuelson O, Alaupovic P. Lipoprotein Metabolism and renal failure. Am J kidney dis 1993;21:573-592.
9. Attman P.O, Alaupovic P. serum apolipoprotein profiles of patients with chronic renal failure. Kidney Int 1987;32:368-375.
10. Kambiz Farbaksh, Bertam L Kasiske. Dyslipidemia in patients who have chronic kidney disease. The medical clinics of North America 2005;89:689-699.
11. Thomas Quaschnig, Vera Krane, Thomas Metzger, Christoph Wanner. Abnormalities in uremic Lipoprotein Metabolism and its impact on cardiovascular disease. Am J kidney dis 2001;38:S14-S19.
12. John D. Bagdade, John J. Albers. Plasma high density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 1977;1436-39.
13. Marion Morena, Jean-Paul Cristol, thierryDantoine,Marrie-Annette Carbonneau, Bernard Descomps, Bernard Canaud et al. protective effects of highdebsnity lipoprotein against oxidative stress are impaired in haemodialysispatients. Nephrol Dial Transplant 2000;15:389-393.
14. SM Alam, AK Bhatt. Abnormal lipoprotein in uremic patients treated conservatively and by maintainance hemodialysis. J Assoc phy India 1991;99:170-171.
15. L.S Ibels, L.A Simons, J.O King, P.F Williams,F.C Neale, JH Stewart et al. Studies on the nature and causes of hyperlipidemia in uremia, maintenance dialysis and renal transplantation. Quart J Med 1975;176:601-614.

Subscription Information:

(Also available at www.ijhrmlp.org)

- Members of ijhrmlp will get the Journal Copy (both hard and soft) Free of Cost. However for home delivery he/she is to pay the postal charge/self stamped A4 sized envelope.
- The entire contributory author will get free copy at their address.
- Personal subscriptions: In India, Rs. 500/, Rest of the World, US 100/-
- **Institutions:** In India, Rs. 1000/, Rest of the World, US 200/-
- We accept Bank Cheque / Demand Draft / Online Transfer

BANK DETAILS

Bank Account Name: International Journal of Health Research and Medico Legal Practice (**Short form:** Int. J. Health Res. Medico Leg. Prac.)

Account No: 1329104000014571

Bank Name: IDBI Bank

Branch: Beltola, Guwahati, Assam, India

IFSC Code: IBKL0001329